Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS), and Cardiac Resynchronization Therapy Defibrillator (CRT-D)] and Geography (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2014-2022Implantable defibrillators is a battery-powered small device placed underneath chest or abdomen to keep track of patient’s heart rate. Increase in palpitation is diagnosed by the device and the normal heart rhythm is restored. These devices play a vital role in preventing sudden cardiac arrest in patients who suffer from sustained ventricular tachycardia or atrial fibrillation. Therefore, ICDs constantly monitor the heart rhythm through electrodes and deliver treatments when abnormal heart rhythm is detected. The treatments through ICDs include pacing, cardioversion, and defibrillation to restore normal heart rhythm.
The implantable defibrillator market was valued at $6,006 million in 2015, and is projected to reach $8,449 million by 2022, growing at a CAGR of 4.9% from 2016 to 2022. This is attributed to the advancements in the technology such as introduction of quadripolar lead devices to improve device programming, extend battery life, and development of magnetic resonance imaging (MRI)-safe ICDs. In addition, rise in incidence of atrial fibrillation and high risk of sudden cardiac arrest (SCA) fuel the demand for implantable defibrillator devices. Furthermore, introduction of subcutaneous ICD technology in 2012 has revolutionized the treatment technology for cardiac rhythm management through these devices. Boston Scientific’s S-ICDs was granted market clearance in 2012, which was the first commercially available S-ICDs system worldwide. S-ICDs are widely adopted, as they are implanted below the skin without the leads to be placed inside the heart. This fueled the demand for S-ICDs globally, thus driving the growth of the market. However, presence of alternative treatment and limited insurance coverage are projected to hamper the market growth.
The implantable defibrillator market is segmented based on product type and geography. On the basis of product type, the market is segmented into transvenous implantable cardioverter-defibrillator (T-ICDs), subcutaneous implantable cardioverter defibrillators (S-ICDS), and cardiac resynchronization therapy defibrillator (CRT-D). Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Argentina, Egypt, Israel, South Africa, and rest of LAMEA).
This report provides an extensive analysis of the current & emerging market trends and dynamics in the global implantable defibrillator market.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise market conditions are analyzed in the report.
KEY MARKET SEGMENTS
By Product Type
Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. KEY PLAYERS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2. EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3. MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.2.3. Top player positioning
3.3. MARKET DYNAMICS
184.108.40.206. Rising incidence of sudden cardiac arrest (SCA)
220.127.116.11. Technologically advanced implantable defibrillators
18.104.22.168. Presence of high unmet medical needs
22.214.171.124. Limited insurance coverage
126.96.36.199. Presence of alternative mode of treatment
188.8.131.52. Lucrative opportunities in emerging economies
CHAPTER 4. IMPLANTABLE DEFIBRILLATORS MARKET, BY PRODUCT TYPE
4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.2. SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (S-ICDS)
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (T-ICDS)
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D)
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5. IMPLANTABLE DEFIBRILLATORS MARKET, BY REGION
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Growth factors and opportunities
5.2.3. Market size and forecast by Country
5.2.4. Market size and forecast by Product
184.108.40.206. U.S. market size and forecast
220.127.116.11. Canada market size and forecast
18.104.22.168. Mexico market size and forecast
5.3.1. Key market trends
5.3.2. Growth factors and opportunities
5.3.3. Market size and forecast by Country
5.3.4. Market size and forecast by Product
22.214.171.124. UK market size and forecast
126.96.36.199. Germany market size and forecast
188.8.131.52. France market size and forecast
184.108.40.206. Italy market size and forecast
220.127.116.11. Spain market size and forecast
18.104.22.168. Rest of Europe market size and forecast
5.4.1. Key market trends
5.4.2. Growth factors and opportunities
5.4.3. Market size and forecast by Country
5.4.4. Market size and forecast by Product
22.214.171.124. Japan market size and forecast
126.96.36.199. India market size and forecast
188.8.131.52. China market size and forecast
184.108.40.206. Australia market size and forecast
220.127.116.11. Rest of Asia-Pacific market size and forecast
5.5.1. Key market trends
5.5.2. Growth factors and opportunities
5.5.3. Market size and forecast by Country
5.5.4. Market size and forecast by Product
18.104.22.168. Brazil market size and forecast
22.214.171.124. Argentina market size and forecast
126.96.36.199. Egypt market size and forecast
188.8.131.52. Israel market size and forecast
184.108.40.206. South Africa market size and forecast
220.127.116.11. Rest of LAMEA market size and forecast
CHAPTER 6. COMPANY PROFILES
6.1. BOSTON SCIENTIFIC CORPORATION
6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments
6.2. LIVANOVA PLC COMPANY
6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments
6.3. IMRICOR MEDICAL SYSTEMS
6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments
6.4. MICROPORT SCIENTIFIC CORPORATION
6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments
6.5. MAYO CLINIC US
6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments
6.6. MEDTRONIC PLC
6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments
6.7. MRI INTERVENTIONS, INC.
6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments
6.8. ST. JUDE MEDICAL, INC.
6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments
6.9. BIOTRONIK SE & CO.KG
6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments
6.10. SORIN GROUP
6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments
Implantable defibrillators are used to prevent sudden death in patients who sustained atrial fibrillation or ventricular tachycardia. These devices are implanted inside the patients body and are able to perform defibrillation, pacing of the heart, and cardioversion. The irregular heart rhythms that require ICD implant include bradycardia, ventricular tachycardia, and ventricular fibrillation.
Surge in geriatric population; increase in prevalence of chronic health conditions such as cardiac arrhythmia, ventricular fibrillation, and pulseless ventricular tachycardia, growth in preference for S-ICDs, and rise in in awareness among patients about implantable defibrillators are expected to drive the market growth. However, lack of awareness towards the availability of implantable defibrillator to prevent sudden cardiac arrest (SCA) and adoption of these devices in low- and middle-income economies are projected to hamper the market growth.
Transvenous implantable cardioverter-defibrillator (T-ICDs) segment dominated the global market in 2015, in terms of value, and is expected to maintain this trend throughout the analysis period. T-ICDs are the most commonly for the treatment of heart disorders for higher precision and targeted functioning. However, in terms of volume, CRT-D is projected to lead the market, reaching 1,127 thousand units by 2022, registering a CAGR of 8.9%.
North America led the global market in 2015, and is expected to maintain its dominance during the forecast period. This is attributed to the rise in incidence of sudden cardiac arrest (SCA), increase in adoption of S-ICDs, high purchasing power, and availability of advanced healthcare facilities.
Key Findings of Implantable Defibrillators Market
In 2015, T-ICDs led the overall implantable defibrillator market revenue, and is projected to grow at a CAGR of 4.9% during the forecast period.
The CRT-D segment occupied the highest share in 2015, and is expected to grow at a CAGR of 8.9%, in terms of volume.
North America was the leading consumer of implantable defibrillators in 2015, both in terms of value and volume, followed by Europe.
Japan is expected to lead market in the Asia-Pacific region, growing at a CAGR 6.2%.
Key players operating in the market include Boston Scientific Corporation, LivaNova PLC Company, Imricor Medical Systems, MicroPort Scientific Corporation, Mayo Clinic US, Medtronic plc, MRI Interventions, Inc., St. Jude Medical, Inc., Biotronik Se & Co.KG, and Sorin Group.
- Boston Scientific Corporation
- LivaNova PLC Company
- Imricor Medical Systems
- MicroPort Scientific Corporation
- Mayo Clinic US
- Medtronic Plc
- MRI Interventions, Inc.
- St. Jude Medical, Inc.
- Biotronik Se & Co.KG
- Sorin Group